G1 Therapeutics, Inc

Almac Diagnostic Service is a leading provider of precision medicine solutions, offering a wide range of genomic services and diagnostic assays for clinical trials and companion diagnostics. With state-of-the-art laboratories in the UK, US, and Asia, they provide global clinical trial testing and sample management services, along with expertise in data sciences and bioinformatics. Additionally, Almac Diagnostic Service offers consultancy services and a unique gene expression report called claraT. They are part of the Almac Group, a global bioPharma partner known for their advanced platforms and technologies in DNA and RNA sequencing, as well as liquid biopsy solutions. With a strong focus on quality management and a commitment to innovation, Almac Diagnostic Service is at the forefront of biomarker discovery and clinical support in the field of precision medicine.Generated from the website

Evecxia Therapeutics, Inc., based in Durham, NC, is a pioneering pharmaceutical company dedicated to improving the lives of individuals with mental illness. With a focus on serotonin synthesis amplification, Evecxia is at the forefront of developing innovative drug delivery technologies to harness the therapeutic potential of 5-hydroxytryptamine (5-HTP), the natural precursor of serotonin. By amplifying the production of natural brain serotonin, Evecxia aims to provide more effective treatment options for individuals suffering from mental illnesses that are not adequately addressed by current therapies. Driven by the mission to help individuals lead fuller and more meaningful lives, Evecxia Therapeutics is committed to addressing the negative impact of mental illness on various aspects of life, including emotional well-being, work performance, and relationships. By leveraging their expertise in serotonin neurotransmission, Evecxia is developing novel drug candidates that have shown promise in clinical settings, particularly as adjunctive therapies for depression. Through their innovative approach, Evecxia Therapeutics aims to revolutionize the treatment of mental illnesses and provide new hope for those in need.Generated from the website

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that treat cancer, cardiovascular and autoimmune diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling. In structure-based drug design, scientists use detailed knowledge of the active sites of protein targets associated with particular diseases to design synthetic compounds that fight the disease. Structure-based drug design aims to create a molecule that will bind to the active site of a targeted enzyme, thereby preventing the normal chemical reaction and ultimately halting the progression of the disease. BioCryst was founded in 1986. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.